Table 2.
Signaling pathways targeted in clinical trials for the inhibition of various cancers (modified from [105])
| Cancer type | Targeted signaling pathway | Therapy: mono- or combination |
|---|---|---|
| Colon cancer | STAT/β-β-catenin /Nanog | Combination |
| Stomach cancer | STAT/β-β-catenin /Nanog | Monotherapy Combination |
| GI cancer | STAT/β-β-catenin /Nanog | Combination |
| Hepatocellular carcinoma | STAT/β-β-catenin /Nanog Wnt/FZD8Fc/FAK |
Combination Combination |
| Mesothelioma | FAK | Monotherapy |
| Squamous cell lung cancer | Notch FAK |
Combination Monotherapy |
| Testicular cancer | Notch FAK |
Combination Combination |
| Pancreas cancer | STAT/β-β-catenin /Nanog Notch | Combination Combination |
| Small cell lung cancer | Notch | Combination |